Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Shanghai Pharma Forms $250 Million China Antibody JV with Russia's Biocad

publication date: Sep 17, 2019

Shanghai Pharmaceuticals formed a JV with Russian biopharma Biocad that will include an initial investment of $250 million and is expected to lead to a $2.8 billion capitalization. The JV will develop six Biocad monoclonal antibodies targeting cancer and autoimmune diseases for China's market, some or them novel drugs and the rest biosimilars. The initial $250 million investment will underwrite China clinical trials. Originally announced via an MOU signed last year, the partnership was formally inaugurated early this summer in a Moscow ceremony. More details....

Stock Symbol: (HK: 2605)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital